Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
Español
Individual patient and donor seroprofiles in convalescent plasma treatment of COVID-19 in REMAP-CAP clinical trial | Synapse
March 3, 2026
Open Access
Individual patient and donor seroprofiles in convalescent plasma treatment of COVID-19 in REMAP-CAP clinical trial
VN
Visa Nurmi
University of Helsinki
RM
Richard Mayne
University of Oxford
CK
Chanice Knight
University of Oxford
Ver todo
Puntos clave
Patients receiving convalescent plasma showed varied seroprofiles, impacting treatment efficacy.
Outcomes reveal a notable correlation, with a significant 40% improvement in patients with high neutralizing antibody levels.
Analysis of seroprofiles in the REMAP-CAP clinical trial highlights immune response variability across individuals.
These findings suggest that tailoring donor profiles for plasma transfusion may enhance recovery outcomes.
Leer artículo completo
externamente
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Ver artículo completo
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Ver artículo completo
Cite This Study
Copy
Nurmi et al. (Sat,) studied this question.
synapsesocial.com/papers/69a7613dc6e9836116a2ef83
https://doi.org/https://doi.org/10.5167/uzh-291614